Whole Cell Cholera Vaccine , by End User (Pediatrics, Adults): Global Opportunity Analysis and Industry Forecast, 2023-2032

Cholera is a chronic disease associated with diarrhea and immediate treatment is essential as death is inevitable if the disease is left untreated. Cholera is an acute infection caused by the bacterium Vibrio cholerae. It is anticipated to be a global threat to public health especially in regions that lack social development. Thus, oral cholera vaccines are utilized to supplement the management of the disease globally.

The factors that fuel the growth of the global whole cell cholera vaccine (recombinant B-subunit) market are rising incidence of cholera among people in endemic regions along with a lack of sanitation and hygiene in certain countries. In addition, according to WHO in 2015, cholera was responsible for 21,000 to 143,000 deaths globally. However, longer timelines required to produce vaccines and high monetary inputs associated with the same restrain the market growth. But recent outbreaks of cholera in certain countries will offer lucrative opportunities for the market growth.

The market is segmented based on end user and region. Based on end user, the market is segmented into pediatrics and adults. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players that operate in the market are SBL Vaccine, PaxVax, Inc., Valneva SE, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur, AstraZeneca Plc. (Medimmune, LLC.), and Serum Institute of India Pvt. Ltd.

Key Benefits

• The study provides an in-depth analysis of the global whole cell cholera vaccine (recombinant B-subunit) market with current trends and future estimations to elucidate imminent investment pockets.
• It presents a quantitative analysis to enable stakeholders to capitalize on prevailing market opportunities.
• Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.
• By region, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

  Whole Cell Cholera Vaccine , by End User Report Highlights

Aspects	Details
By End User	Pediatrics Adults
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Argentina, Rest of LAMEA)
Key Market Players	Valneva SE,, AstraZeneca Plc. (Medimmune, LLC.),, Pfizer Inc.,, Serum Institute of India Pvt. Ltd., SBL Vaccine,, Johnson & Johnson,, Merck & Co., Inc.,, Sanofi Pasteur,, PaxVax, Inc.,, GlaxoSmithKline Plc.,

^*Terms and Conditions Apply